Nanoencapsulated Cannabidiol Time Released Capsules Targeted to Reduce Cravings in the Treatment of Opioid Addiction
Latest Information Update: 04 Nov 2021
At a glance
- Drugs APH 1501 (Primary)
- Indications Drug dependence; Opioid-related disorders; Substance-related disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Aphios Pharma
- 15 Jul 2019 Planned number of patients changed from 30 to 32.
- 15 Jul 2019 Planned End Date changed from 1 Jun 2022 to 1 Dec 2025.
- 15 Jul 2019 Planned primary completion date changed from 1 Dec 2021 to 1 Sep 2025.